BE2011C030I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2011C030I2 BE2011C030I2 BE2011C030C BE2011C030C BE2011C030I2 BE 2011C030 I2 BE2011C030 I2 BE 2011C030I2 BE 2011C030 C BE2011C030 C BE 2011C030C BE 2011C030 C BE2011C030 C BE 2011C030C BE 2011C030 I2 BE2011C030 I2 BE 2011C030I2
- Authority
- BE
- Belgium
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Surgery (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46121503P | 2003-04-08 | 2003-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2011C030I2 true BE2011C030I2 (pl) | 2023-03-07 |
Family
ID=32326722
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2004/0180A BE1015972A5 (fr) | 2003-04-08 | 2004-04-07 | Composes organiques. |
| BE2011C030C BE2011C030I2 (pl) | 2003-04-08 | 2011-09-08 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2004/0180A BE1015972A5 (fr) | 2003-04-08 | 2004-04-07 | Composes organiques. |
Country Status (41)
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527055T3 (es) * | 2004-07-30 | 2015-01-20 | Novartis Ag | Formulaciones de compuestos 2-amino-1,3-propanodiol |
| CN1891212B (zh) * | 2005-07-07 | 2010-10-13 | 马启明 | 一种口服制剂及其制备方法 |
| JO2655B1 (en) * | 2005-09-09 | 2012-06-17 | نوفارتيس ايه جي | Treatment of autoimmune diseases |
| JP5436860B2 (ja) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス， インク． | 酵素阻害のための化合物 |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| MY183014A (en) | 2006-06-19 | 2021-02-05 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
| GB0612721D0 (en) | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| AU2011235934A1 (en) * | 2006-09-26 | 2011-11-03 | Novartis Ag | Pharmaceutical compositions comprising an S1P modulator |
| EP1923055A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator |
| EP1923058A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Coated pharmaceutical composition comprising an S1P agonist or modulator |
| EP1905434A1 (en) * | 2006-09-26 | 2008-04-02 | Novartis AG | Organic compounds comprising an S1P receptor agonist and their therapeutic use |
| EP1923054A1 (en) * | 2006-09-26 | 2008-05-21 | Novartis AG | Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator |
| KR101884047B1 (ko) * | 2006-09-26 | 2018-07-31 | 노파르티스 아게 | Ｓ１ｐ 조정제를 포함하는 제약 조성물 |
| WO2008124210A1 (en) * | 2007-02-14 | 2008-10-16 | Emory University | Methods and compositions for treating or preventing infection using leukocyte sequestration agents |
| KR101424843B1 (ko) | 2007-03-29 | 2014-08-13 | 다이이찌 산쿄 가부시키가이샤 | 의약 조성물 |
| KR20150131405A (ko) | 2007-10-04 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| AU2012216630B2 (en) * | 2007-10-12 | 2015-01-22 | Novartis Ag | Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators |
| ES2545361T3 (es) * | 2007-10-12 | 2015-09-10 | Novartis Ag | Composiciones que comprenden moduladores del receptor de esfingosina 1-fosfato (S1P) |
| JP5534645B2 (ja) * | 2008-01-11 | 2014-07-02 | 日医工株式会社 | 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤 |
| WO2009099174A1 (ja) | 2008-02-07 | 2009-08-13 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| HRP20170246T4 (hr) | 2008-03-17 | 2020-02-07 | Actelion Pharmaceuticals Ltd. | Režim doziranja za selektivni agonist s1p1-receptora |
| RU2519768C2 (ru) * | 2008-06-20 | 2014-06-20 | Мерк Патент Гмбх | Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки |
| CA2728514C (en) | 2008-06-20 | 2020-08-11 | Novartis Ag | Paediatric compositions for treating multiple sclerosis |
| PT2334202E (pt) * | 2008-09-04 | 2012-02-28 | Cargill Inc | Fabrico de comprimidos de eritritol |
| JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| AU2013100532B4 (en) * | 2008-11-11 | 2013-11-28 | Novartis Ag | Crystalline forms of fingolimod HCL |
| ES2643161T3 (es) | 2008-11-11 | 2017-11-21 | Novartis Ag | Formas cristalinas de HCL de fingolimod |
| AU2009315735B2 (en) | 2008-11-11 | 2013-01-10 | Novartis Ag | Salts of fingolimod |
| KR101463653B1 (ko) | 2008-12-17 | 2014-11-19 | 다이이찌 산쿄 가부시키가이샤 | 디아민 유도체의 제조 방법 |
| WO2010082531A1 (ja) | 2009-01-13 | 2010-07-22 | 第一三共株式会社 | 活性化血液凝固因子阻害剤 |
| ES2542236T3 (es) | 2009-03-10 | 2015-08-03 | Daiichi Sankyo Company, Limited | Procedimiento de producción de un derivado de diamina |
| EP2407450B1 (en) | 2009-03-13 | 2015-04-22 | Daiichi Sankyo Company, Limited | Method for producing optically active diamine derivative |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| EP2444087B1 (en) * | 2009-06-18 | 2016-09-07 | Daiichi Sankyo Company, Limited | Pharmaceutical composition having improved solubility |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| CA2791651C (en) | 2010-03-01 | 2019-08-20 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| JP5692873B2 (ja) | 2010-03-19 | 2015-04-01 | 第一三共株式会社 | ジアミン誘導体の結晶およびその製造方法 |
| ES2601884T3 (es) | 2010-03-19 | 2017-02-16 | Daiichi Sankyo Company, Limited | Procedimiento para mejorar la capacidad de disolución de un anticoagulante |
| US20130095177A1 (en) * | 2010-04-22 | 2013-04-18 | Ratiopharm Gmbh | Method of preparing an oral dosage form comprising fingolimod |
| HUE031961T2 (en) | 2010-07-02 | 2017-09-28 | Daiichi Sankyo Co Ltd | A method for preparing an optically active salt of diamine derivative |
| WO2012070059A1 (en) | 2010-11-25 | 2012-05-31 | Shilpa Medicare Limited | Fingolimod polymorphs and their processes |
| ES2751920T3 (es) | 2011-01-07 | 2020-04-02 | Novartis Ag | Formulaciones inmunosupresoras |
| HUE038543T2 (hu) | 2011-01-19 | 2018-10-29 | Pathologica Llc | MGBG-t tartalmazó szabályozott kibocsátású orális gyógyszerészeti dózis-formák |
| JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
| US9186333B2 (en) * | 2011-08-01 | 2015-11-17 | Teva Pharmaceutical Industries Ltd. | Process for preparing pharmaceutical compositions of fingolimod |
| JPWO2013022059A1 (ja) | 2011-08-10 | 2015-03-05 | 第一三共株式会社 | ジアミン誘導体含有医薬組成物 |
| WO2013091704A1 (en) | 2011-12-22 | 2013-06-27 | Synthon Bv | Pharmaceutical composition comprising fingolimod |
| RU2482842C1 (ru) * | 2012-04-26 | 2013-05-27 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения |
| RU2506949C1 (ru) * | 2012-06-13 | 2014-02-20 | Открытое акционерное общество "Новосибхимфарм" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| RU2496486C1 (ru) * | 2012-07-11 | 2013-10-27 | Александр Васильевич Иващенко | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
| JP6370804B2 (ja) | 2013-01-08 | 2018-08-08 | パソロジカ エルエルシー | 脱髄疾患の治療のための方法および組成物 |
| WO2014141298A2 (en) * | 2013-03-11 | 2014-09-18 | Astron Research Limited | Stable pharmaceutical composition of fingolimod |
| US9629834B2 (en) * | 2013-04-26 | 2017-04-25 | Kyoto University | Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same |
| ES2770500T3 (es) * | 2013-05-13 | 2020-07-01 | Synthon Bv | Composición farmacéutica que comprende fingolimod |
| JP6316422B2 (ja) * | 2013-07-29 | 2018-04-25 | アイザント ドラッグ リサーチ ソリューションズ プライベート リミテッドＡｉｚａｎｔ Ｄｒｕｇ Ｒｅｓｅａｒｃｈ Ｓｏｌｕｔｉｏｎｓ Ｐｖｔ Ｌｔｄ | フィンゴリモドの医薬組成物 |
| RU2530626C1 (ru) * | 2013-10-21 | 2014-10-10 | Ооо "Валента-Интеллект" | Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний |
| WO2016026461A1 (en) * | 2014-08-22 | 2016-02-25 | Sunshine Lake Pharma Co., Ltd. | Solid composition of fingolimod and preparation thereof |
| WO2016042493A1 (en) * | 2014-09-19 | 2016-03-24 | Aizant Drug Research Pvt. Ltd | Pharmaceutical compositions of fingolimod |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
| RU2577230C1 (ru) * | 2015-04-09 | 2016-03-10 | Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" | Способ получения капсул финголимода гидрохлорида |
| US9690975B2 (en) * | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11434200B2 (en) | 2017-03-09 | 2022-09-06 | Novartis Ag | Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof |
| WO2018178744A1 (en) | 2017-03-29 | 2018-10-04 | Deva Holding Anonim Sirketi | Stable formulations of fingolimod |
| GR1009654B (el) | 2018-08-31 | 2019-11-18 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| DE102018217334A1 (de) * | 2018-10-10 | 2020-04-16 | Harbins Ruhr Bioscience, Inc. | Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel |
| JP7503420B2 (ja) * | 2020-05-18 | 2024-06-20 | 東和薬品株式会社 | フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法 |
| AR122175A1 (es) | 2020-05-29 | 2022-08-24 | Myovant Sciences Gmbh | Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina |
| US11298412B2 (en) | 2020-07-16 | 2022-04-12 | Harbins Ruhr Bioscience, Inc. | Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection |
| AU2021424131A1 (en) * | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
| CA3208122A1 (en) * | 2021-01-28 | 2022-08-04 | Priothera Sas | Methods of treatment with s1p receptor modulators |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7607683A (nl) * | 1976-07-12 | 1978-01-16 | Akzo Nv | Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan. |
| US4110332A (en) * | 1977-05-05 | 1978-08-29 | Chevron Research Company | 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones |
| US4559153A (en) | 1983-10-25 | 1985-12-17 | Phillips Petroleum Company | Metal working lubricant |
| US5112616A (en) * | 1988-11-30 | 1992-05-12 | Schering Corporation | Fast dissolving buccal tablet |
| JP2841857B2 (ja) * | 1990-11-29 | 1998-12-24 | 田辺製薬株式会社 | 長期間安定な経口用医薬製剤 |
| DE69321823T2 (de) | 1992-10-21 | 1999-06-02 | Taito Co., Ltd., Tokio/Tokyo | 2-amino-1, 3- propandiolverbindung und immunosuppressium |
| ES2171191T3 (es) | 1994-08-22 | 2002-09-01 | Mitsubishi Pharma Corp | Compuesto de benceno y uso medicinal del mismo. |
| ES2230571T3 (es) | 1995-12-28 | 2005-05-01 | Mitsubishi Pharma Corporation | `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria. |
| JP2002241272A (ja) * | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| JPH11209277A (ja) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | 医薬組成物 |
| US6476004B1 (en) * | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
| GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| CN1178653C (zh) * | 1997-02-27 | 2004-12-08 | 三菱制药株式会社 | 药物组合物 |
| DK1002792T3 (da) * | 1997-04-04 | 2004-11-22 | Mitsubishi Pharma Corp | 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| JP3545595B2 (ja) | 1998-04-01 | 2004-07-21 | 花王株式会社 | スフィンゴ糖脂質の製造法 |
| JP4627356B2 (ja) | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| WO2001003739A1 (fr) * | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
| KR100812578B1 (ko) | 2000-07-13 | 2008-03-13 | 상꾜 가부시키가이샤 | 아미노알코올 유도체 |
| WO2002018395A1 (en) * | 2000-08-31 | 2002-03-07 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
| US6953332B1 (en) | 2000-11-28 | 2005-10-11 | St. Jude Medical, Inc. | Mandrel for use in forming valved prostheses having polymer leaflets by dip coating |
| DK1377593T3 (da) | 2001-03-26 | 2006-04-10 | Novartis Ag | 2-Amino-propanolderivater |
| US7521192B2 (en) * | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| US20040235794A1 (en) | 2001-09-04 | 2004-11-25 | Shinji Nakade | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| PT1431284E (pt) | 2001-09-27 | 2008-01-21 | Kyorin Seiyaku Kk | Derivado de sulfureto de diarilo, um seu sal de adição e imunossupressor |
| US6963012B2 (en) | 2001-09-27 | 2005-11-08 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| DE60329073D1 (de) | 2002-01-18 | 2009-10-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| AU2003202994B2 (en) | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| EP1469863A2 (en) | 2002-01-18 | 2004-10-27 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| CA2473740A1 (en) | 2002-01-18 | 2003-07-31 | David Solow-Cordero | Methods of treating conditions associated with an edg receptor |
| BRPI0513110A (pt) * | 2004-07-16 | 2008-04-29 | Kyorin Seiyaku Kk | medicamento compreendendo composto sulfeto diaril ou composto éter diaril tendo uma estrutura 2-amina-1, 3-propanediol tendo uma atividade de redução de linfócitos perifericamente circulante, em combinação com um agente imunosupressivo e/ou um agente antiinflamatório e método de expressão de prevenção do efeito secundário |
-
2004
- 2004-04-06 PE PE2012002027A patent/PE20130200A1/es not_active Application Discontinuation
- 2004-04-06 ES ES200400852A patent/ES2228282B1/es not_active Expired - Fee Related
- 2004-04-06 EP EP10184951.1A patent/EP2316431B1/en not_active Revoked
- 2004-04-06 DK DK10184951.1T patent/DK2316431T3/en active
- 2004-04-06 PE PE2015000303A patent/PE20150676A1/es not_active Application Discontinuation
- 2004-04-06 IT IT000682A patent/ITMI20040682A1/it unknown
- 2004-04-06 GB GB0407819A patent/GB2400318B/en not_active Expired - Lifetime
- 2004-04-06 WO PCT/EP2004/003656 patent/WO2004089341A1/en not_active Ceased
- 2004-04-06 SI SI200431037T patent/SI1613288T1/sl unknown
- 2004-04-06 SI SI200432283T patent/SI2316431T1/sl unknown
- 2004-04-06 AT ATA606/2004A patent/AT501681B1/de not_active IP Right Cessation
- 2004-04-06 HR HR20100600A patent/HRP20100600A2/hr not_active Application Discontinuation
- 2004-04-06 US US10/552,005 patent/US20060275357A1/en not_active Abandoned
- 2004-04-06 CA CA2707750A patent/CA2707750A1/en not_active Abandoned
- 2004-04-06 ES ES04725895T patent/ES2320767T3/es not_active Expired - Lifetime
- 2004-04-06 NZ NZ586280A patent/NZ586280A/en not_active IP Right Cessation
- 2004-04-06 MX MXPA05010860A patent/MXPA05010860A/es active IP Right Grant
- 2004-04-06 HR HRP20100601AA patent/HRP20100601B1/hr not_active IP Right Cessation
- 2004-04-06 CN CN2010101213007A patent/CN101797241B/zh not_active Expired - Lifetime
- 2004-04-06 GR GR20040100121A patent/GR1005052B/el unknown
- 2004-04-06 DE DE602004017847T patent/DE602004017847D1/de not_active Expired - Lifetime
- 2004-04-06 PT PT04725895T patent/PT1613288E/pt unknown
- 2004-04-06 ES ES10184951.1T patent/ES2556947T3/es not_active Expired - Lifetime
- 2004-04-06 PE PE2008001684A patent/PE20090743A1/es not_active Application Discontinuation
- 2004-04-06 AU AU2004228929A patent/AU2004228929B2/en not_active Expired
- 2004-04-06 SG SG2008040545A patent/SG175449A1/en unknown
- 2004-04-06 CA CA2521325A patent/CA2521325C/en not_active Expired - Lifetime
- 2004-04-06 EP EP14163450.1A patent/EP2769713A1/en not_active Withdrawn
- 2004-04-06 EP EP04725895A patent/EP1613288B1/en not_active Expired - Lifetime
- 2004-04-06 AT AT04725895T patent/ATE414508T1/de active
- 2004-04-06 DK DK04725895T patent/DK1613288T3/da active
- 2004-04-06 KR KR1020127019448A patent/KR101367574B1/ko not_active Expired - Lifetime
- 2004-04-06 PL PL10184951.1T patent/PL2316431T3/pl unknown
- 2004-04-06 DE DE202004021680U patent/DE202004021680U1/de not_active Expired - Lifetime
- 2004-04-06 NZ NZ542622A patent/NZ542622A/xx not_active IP Right Cessation
- 2004-04-06 HR HR20050886A patent/HRP20050886B1/xx not_active IP Right Cessation
- 2004-04-06 KR KR1020107029859A patent/KR20110005320A/ko not_active Ceased
- 2004-04-06 DE DE102004016947A patent/DE102004016947A1/de not_active Ceased
- 2004-04-06 RU RU2005134173/15A patent/RU2358716C2/ru not_active IP Right Cessation
- 2004-04-06 PE PE2004000355A patent/PE20050396A1/es not_active Application Discontinuation
- 2004-04-06 PL PL04725895T patent/PL1613288T3/pl unknown
- 2004-04-06 PE PE2013000382A patent/PE20131352A1/es active IP Right Grant
- 2004-04-06 BR BRPI0409250A patent/BRPI0409250B8/pt active IP Right Grant
- 2004-04-06 HU HUE10184951A patent/HUE028247T2/en unknown
- 2004-04-06 AR ARP040101162A patent/AR043987A1/es not_active Application Discontinuation
- 2004-04-06 DE DE201112100047 patent/DE122011100047I1/de active Pending
- 2004-04-06 NZ NZ592339A patent/NZ592339A/xx not_active IP Right Cessation
- 2004-04-06 KR KR1020057019066A patent/KR20050121712A/ko not_active Ceased
- 2004-04-06 JP JP2004111761A patent/JP5495467B2/ja not_active Expired - Lifetime
- 2004-04-06 CN CN2004800092370A patent/CN1767819B/zh not_active Expired - Lifetime
- 2004-04-06 FR FR0450692A patent/FR2854073B1/fr not_active Expired - Lifetime
- 2004-04-06 EP EP08161161A patent/EP2008650A3/en not_active Withdrawn
- 2004-04-06 EP EP10186307A patent/EP2319502A1/en not_active Withdrawn
- 2004-04-07 MY MYPI20041275A patent/MY141249A/en unknown
- 2004-04-07 CL CL200400745A patent/CL2004000745A1/es unknown
- 2004-04-07 BE BE2004/0180A patent/BE1015972A5/fr not_active IP Right Cessation
- 2004-04-07 TW TW093109631A patent/TWI332847B/zh active
-
2005
- 2005-09-14 ZA ZA200507394A patent/ZA200507394B/en unknown
- 2005-09-15 IL IL170888A patent/IL170888A/en active IP Right Grant
- 2005-10-07 TN TNP2005000256A patent/TNSN05256A1/en unknown
- 2005-10-07 EC EC2005006090A patent/ECSP056090A/es unknown
- 2005-10-19 MA MA28560A patent/MA27729A1/fr unknown
- 2005-11-01 IS IS8114A patent/IS2682B/is unknown
- 2005-11-07 NO NO20055231A patent/NO329332B1/no active Protection Beyond IP Right Term
-
2008
- 2008-05-08 AT AT0074408A patent/AT504853A2/de not_active Application Discontinuation
- 2008-08-11 US US12/189,323 patent/US8324283B2/en not_active Expired - Fee Related
- 2008-08-13 US US12/191,098 patent/US20090203798A1/en not_active Abandoned
-
2009
- 2009-02-17 RU RU2009105403/15A patent/RU2009105403A/ru not_active Application Discontinuation
- 2009-02-19 CY CY20091100192T patent/CY1110260T1/el unknown
- 2009-03-12 IL IL197578A patent/IL197578A/en active IP Right Grant
-
2010
- 2010-02-18 NO NO20100250A patent/NO334116B1/no unknown
- 2010-02-25 IS IS8885A patent/IS8885A/is unknown
- 2010-08-25 JP JP2010188835A patent/JP5543298B2/ja not_active Expired - Lifetime
- 2010-10-26 AR ARP100103930A patent/AR078781A2/es not_active Application Discontinuation
- 2010-10-26 AR ARP100103931A patent/AR078782A2/es not_active Application Discontinuation
- 2010-11-17 RU RU2010146697/15A patent/RU2475236C2/ru active
- 2010-11-18 RU RU2010147000/15A patent/RU2475237C2/ru active
-
2011
- 2011-01-10 US US12/987,726 patent/US20110105620A1/en not_active Abandoned
- 2011-03-01 CL CL2011000450A patent/CL2011000450A1/es unknown
- 2011-09-06 HU HUS1100016C patent/HUS1100016I1/hu unknown
- 2011-09-08 LU LU91867C patent/LU91867I2/fr unknown
- 2011-09-08 NO NO2011016C patent/NO2011016I2/no unknown
- 2011-09-08 CY CY2011013C patent/CY2011013I2/el unknown
- 2011-09-08 FR FR11C0036C patent/FR11C0036I2/fr active Active
- 2011-09-08 BE BE2011C030C patent/BE2011C030I2/fr unknown
-
2012
- 2012-11-15 RU RU2012148593/15A patent/RU2012148593A/ru not_active Application Discontinuation
- 2012-12-20 US US13/721,278 patent/US20130108675A1/en not_active Abandoned
-
2013
- 2013-04-23 JP JP2013090602A patent/JP2013177404A/ja active Pending
- 2013-09-16 US US14/027,943 patent/US20140011885A1/en not_active Abandoned
- 2013-09-26 NO NO20131287A patent/NO335120B1/no unknown
-
2014
- 2014-05-23 US US14/285,808 patent/US20140255497A1/en not_active Abandoned
-
2015
- 2015-10-12 IL IL242037A patent/IL242037A0/en unknown
- 2015-12-29 CY CY20151101194T patent/CY1117071T1/el unknown
-
2017
- 2017-06-27 US US15/634,579 patent/US20170290787A1/en not_active Abandoned
-
2019
- 2019-02-13 US US16/274,357 patent/US20190175527A1/en not_active Abandoned
-
2020
- 2020-04-03 US US16/839,703 patent/US20200237690A1/en not_active Abandoned
-
2021
- 2021-10-14 US US17/501,173 patent/US20220031609A1/en not_active Abandoned